spacer
home > pmps > summer 2002 > counterfeit drugs - a clear and present danger
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Counterfeit Drugs - A Clear and Present Danger

Drugs - An Easy Target

The tip of the iceberg is clearly visible and getting larger by the day. Drug counterfeiting and diversion are flourishing in today's world of tumbling international trade barriers, easy global marketing reach via the Internet, and simple access to sophisticated manufacturing and packaging technologies. Drug counterfeiting has steadily evolved from small-scale, opportunistic, activities in less regulated parts of the world to what has now become a widespread global threat to consumers and brand owners. Informed estimates put the size of the annual global market in fake drugs somewhere in the region of US$30 billion, representing about seven per cent of pharmaceutical industry revenue. Even more alarming are results of surveys showing that counterfeit drugs in some countries comprise in excess of 50 per cent of the market. These activities clearly put consumers at risk, threaten corporate and brand integrity, and generate significant cash for organised crime and terrorist groups.

Pharmaceuticals are an attractive target to counterfeiters, mainly because they have a high value in relation to their physical bulk. Consider some of the anti-cancer and anti-HIV treatments where a single pallet of product can represent many millions of dollars - for example, a standard 12-week course of Serostim treatment for HIV/AIDS patients costs approximately US$21,000.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr James Rittenburg, Vice President of Technology and Business Development at Biocode Dr James Rittenburg joined Biocode in 1994 and is currently Vice President of Technology and Business Development. He received his PhD in Microbiology from the University of Maine at Orono in 1981 and has over 20 years' experience developing immunodiagnostic systems for detecting trace levels of chemicals in samples including pharmaceuticals, foods, beverages, petrochemicals and agricultural products.
He has edited several books, authored numerous journal articles and is an inventor on a number of patents in this field. Prior to joining Biocode, James was Director of Product Development for Quantix Systems, where he had responsibility for overseeing the development of immunodiagnostic systems for detecting and measuring environmental pollutants.

spacer
Dr James Rittenburg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PharmaFluidics awarded VLAIO research grant

Ghent, Belgium – June 2, 2020 PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO). The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement